Literature DB >> 26372490

Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1.

Carmela Pinnetti1, Mauro Tintoni, Adriana Ammassari, Enrica Tamburrini, Stefania Bernardi, Giuseppina Liuzzi, Giovanni Scambia, Carlo Federico Perno, Marco Floridia, Andrea Antinori, Anna Franca Cavaliere.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26372490     DOI： 10.1097/QAD.0000000000000888

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  8 in total

1.  Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.

Authors:  Nikki Mulligan; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Alice Stek; Emily Barr; Shelley L Buschur; Edward P Acosta; Elizabeth Smith; Nahida Chakhtoura; Sandra Burchett; Mark Mirochnick
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

2.  Dolutegravir in pregnancy-effects on HIV-positive women and their infants.

Authors:  Riikka Bornhede; Sandra Soeria-Atmadja; Katarina Westling; Karin Pettersson; Lars Navér
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-02       Impact factor: 3.267

Review 3.  Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings.

Authors:  Bluma G Brenner; Ruxandra-Ilinca Ibanescu; Isabelle Hardy; Michel Roger
Journal:  Viruses       Date:  2017-12-28       Impact factor: 5.048

4.  Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review.

Authors:  Andrew Hill; Polly Clayden; Claire Thorne; Rachel Christie; Rebecca Zash
Journal:  J Virus Erad       Date:  2018-04-01

5.  Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy.

Authors:  Clara Grayhack; Anandi Sheth; Olivia Kirby; Jennifer Davis; Kedesha Sibliss; Hervette Nkwihoreze; Erika Aaron; Gregg Alleyne; Roberta Laguerre; Aadia Rana; Martina Badell; Florence Momplaisir
Journal:  AIDS       Date:  2018-09-10       Impact factor: 4.177

6.  Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.

Authors:  Sonya Davey; Gbolahan Ajibola; Kenneth Maswabi; Maureen Sakoi; Kara Bennett; Michael D Hughes; Arielle Isaacson; Modiegi Diseko; Rebecca Zash; Oganne Batlang; Sikhulile Moyo; Shahin Lockman; Mathias Lichterfeld; Daniel R Kuritzkes; Joseph Makhema; Roger Shapiro
Journal:  J Acquir Immune Defic Syndr       Date:  2020-07-01       Impact factor: 3.771

7.  Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing.

Authors:  Joseph M Lewis; Eimear Railton; Andrew Riordan; Saye Khoo; Mas Chaponda
Journal:  AIDS       Date:  2016-05-15       Impact factor: 4.177

8.  Dolutegravir-based anti-retroviral therapy is effective and safe in HIV-infected paediatric patients.

Authors:  Eugenia Bruzzese; Andrea Lo Vecchio; Andrea Smarrazzo; Orsola Tambaro; Giulia Palmiero; Giovanni Bonadies; Alfredo Guarino
Journal:  Ital J Pediatr       Date:  2018-03-20       Impact factor: 2.638
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.